Install
- 31articles · 30d
- 1+ day agolatest article
- Aug 16, 2026earliest in window
- 100%with images
- 246avg words
- Business & Industrial 24
- Economy, Business & Finance 21
- Medical 21
- Science & Technology 9
- Finance & Business 6
- Health & Wellness 6
- Crime & Law 2
- Science & Nature 2
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
3+ day, 23+ hour ago (230+ words) The Pharma Letter - Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib US clinical-stage biotech Tyra Biosciences (Nasdaq: TYRA) yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle…...
Novartis BTK inhibitor clears Phase III hurdle in relapsing MS
1+ week, 5+ day ago (212+ words) The Pharma Letter - Novartis BTK inhibitor clears Phase III hurdle in relapsing MS Swiss pharma major Novartis (NOVN: VX) has reported that its oral candidate remibrutinib significantly cut relapse rates against French drugmaker Sanofi's (Euronext: SAN) Aubagio (teriflunomide) in two Phase…...
Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases
2+ week, 3+ day ago (216+ words) The Pharma Letter - Galen and POA Pharma launch Galsana, a new global brand for rare metabolic diseases Northern Ireland-headquartered pharma company Galen has unveiled Galsana, a new global brand uniting its metabolic disease portfolio with that of Copenhagen-based POA Pharma,…...
Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease
2+ week, 6+ day ago (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...